Home World News EMA Recommends Extension of Indications for Pirtobrutinib World News EMA Recommends Extension of Indications for Pirtobrutinib By Ogkologos - April 24, 2025 921 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Epcoritamab Shows a Manageable Safety and Robust Antitumour Activity in Heavily... September 16, 2021 Preoperative ctDNA Levels Are Detectable in the Majority of Patients with... July 5, 2021 How can we diagnose more cancers earlier? July 27, 2021 Ethnic Diversity and Disparities in Access to Genetic Testing Impact Prostate... November 28, 2022 Load more HOT NEWS Temporary Interruption of Adjuvant Endocrine Treatment to Attempt Pregnancy Does Not... New Research in Treating Non-Small Cell Lung Cancer: 2022 North America... Pausing Long-Term Breast Cancer Therapy to Become Pregnant Appears to Be... EMA Recommends Extension of Therapeutic Indications for Brentuximab Vedotin
